MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Gurnet Point Capital (GPC)
Corium International Inc.-CeMBR
Organization & Developments: Corium
Parents
Corium International Inc.-CeMBR
Children
2014: Adapts its technology to help deliver drugs developed by five partners, two of which have made it to the U.S. market. 2014: Clonidine patch developed with Teva Pharmaceuticals for the treatment of hypertension and ADHD
2014: Corium International plans to raise up to $50 million in an IPO to help with its efforts to develop patches used in drug delivery.
2014: Corium revenue rose from $35.7 million in 2012 to $37.7 million in 2013. During that time its net loss more than doubled from $5.4 million to $13.9 million
2017: Corium International: Room to Run? - Corium International, Inc. (NASDAQ:CORI)
2018: Corium International: What's Ahead_seekingalpha.com
2686 Middlefield Road, Suite G
A Fentanyl patch developed developed with Par Pharmaceuticals for treatment of chronic pain.
Company Engaged in the Research, Development and Manufacture of Advanced Transdermal Drug Delivery Technologies and Products
Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.
Corplex™ enables the "steady-state" delivery of small molecules
MicroCor® is designed for needle-free delivery of large molecules such as proteins and peptides
The company has developed and clinically validated two highly differentiated state of the art transdermal technologies:
Jumps
*Key People: Corium
Finance & Acquisitions: Corium